Sicker Patients for Liver Transplantation: Meld, Meld Sodium, and Integrated Meld’s Prognostic Accuracy in the Assessment of Posttransplantation Events at a Single Center from Argentina

Table 3

Independent variables associated with risk of mortality at 3 months following LT. Multivariate logistic regression analysis.

Variable; (Mean ± SD or %)	Survivors; 𝑛=137	Nonsurvivors; 𝑛=15	P value
MELD	23±7	28±8	0.006
MELD Na1	27±10	33±8	0.046
iMELD	46±8	51±6	0.022
Total bilirubin (mg/dL)*	9±9	16±10	0.006
INR*	2.1±0.9	2.7±1.3	0.043
GFR-MDRD (mL/min)*	75±35	51±25	0.015
Total blood products (units)	41±33	83±51	<0.0001
Hypernatremia >145 mEq/L*	0.7	13.3	0.0009
RRT after LT	2.2	20	0.0008

Note. Normal values: creatinine 0.6–1.1 mg/dL, serum sodium 135–145 mEq/L. ∗Pre-LT variables. Continuous variables are shown as mean ± standard deviation (SD).
DM: diabetes mellitus before LT; GFR-MDRD: glomerular filtration rate calculated by Modification of Diet in Renal Disease equation; MELD: Model for End-Stage Liver Disease: 9.6 × logn (Creat mg/dL) + 3.8 × logn (tot bil mg/dL) + 11.2 × logn (RIN) + 6.4. MELD Na1: MELD sodium 1: MELD + 1.59 × (135 patient's serum sodium mEq/L); MELD Na2: MELD sodium 2: MELD-Na − [0.025 × MELD × (140 − Na)] + 140; iMELD: Integrated MELD: MELD + (age × 0.3) − (0.7 × Na p) + 100; INR: international normalized ratio; BMI: body mass index; CIT: cold ischemic time; WIT: warm ischemic time; RRT: renal replacement therapy; total blood products: Total Blood Products Consumption during the first 48 hrs after liver transplantation; monoclonal antibodies induction: use of Basiliximab (20 mg day 0 and 20 mg day 4); HAT: hepatic artery thrombosis after liver transplantation; PVT: portal vein thrombosis after LT.